Bicara Therapeutics (BCAX) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 0.5% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $543.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | CBIO |
|---|---|---|
| Share price | $8.44 | $13.00 |
| Market cap | $560.31M | $543.21M |
| 1-day change | -7.46% | +0.70% |
| YTD return | -49.85% | +9.61% |
| 1-year return | -53.22% | -0.46% |
| 5-year return | — | -92.74% |
| EPS (TTM) | $-3.46 | $-7.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $10.84M |
| Net income (latest FY) | $-137.95M | $-153.94M |
| Operating margin | — | -1407.52% |
| Net margin | — | -1419.61% |
| 52-week high | $30.99 | $27.41 |
| 52-week low | $7.87 | $8.72 |
| Distance from 52-week high | -72.77% | -52.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +281.16% | +148.69% |
| Average volume | 1.20M | 361.17K |
| Shares outstanding | 66.39M | 38.90M |
| Employees | 103 | 80 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed BCAX by 52.8 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
BCAX vs CBIO FAQ
Which is bigger, Bicara Therapeutics or Crescent Biopharma?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $543.21M for Crescent Biopharma (CBIO).
Which stock has performed better over the past year, BCAX or CBIO?
CBIO returned -0.46% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.